1. Lencioni R, Cioni D, Crocetti L, et al. Early stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005;234:961–7.
2. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int. 2008;7:237–57.
3. Minami Y, Kudo M. Radiofrequency ablation of hepatocellular carcinoma: current status. World J Radiol. 2010;2:417–24.
4. Bruix J, Sherman M. American association for the study of liver diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.
5. Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107:569–77.
6. Kim YS, Lim HK, Rhim H, et al. Ten-year outcomes of percutaneous radiofrequency ablation as frst-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013;58:89–97.
7. Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology. 2004;40:1352–60.
8. Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology. 2005;235:728–39.
9. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.
10. Kim SK, Lim HK, Kim YH, et al. Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging fndings. Radiographics. 2003;23:107–21.
11. Lim HK, Choi D, Lee WJ, et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology. 2001;221:447–54.
12. Barat M, Fohlen A, Cassinotto C, et al. One-month apparent difusion coefcient correlates with response to radiofrequency ablation of hepatocellular carcinoma. J Magn Reson Imaging. 2017;45:1648–58.
13. Yoon JH, Lee EJ, Cha SS, et al. Comparison of gadoxetic acid enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol. 2010;21:348–56.
14. Makino Y, Imai Y, Igura T, et al. Comparative evaluation of threedimensional Gd-EOB-DTPA-enhanced MR fusion imaging with CT fusion imaging in the assessment of treatment efect of radiofrequency ablation of hepatocellular carcinoma. Abdom Imaging. 2015;40:102–11.
15. Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver—update 2012: a WFUMBEFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol. 2013;39:187–210.
16. Westwood M, Joore M, Grutters J, et al. Contrast enhanced ultrasound using SonoVue® (sulphur hexafuoride microbubbles) compared with contrast-enhanced computed tomography and contrastenhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-efectiveness analysis. Health Technol Assess. 2013;17:1–243.
17. Kim CK, Choi D, Lim HK, et al. Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma: utility of contrast-enhanced agent detection imaging. Eur J Radiol. 2005;56:66–73.
18. Vilana R, Bianchi L, Varela M, et al. Is microbubble-enhanced ultrasonography sufcient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma? Eur Radiol. 2006;16:2454–62.
19. Luo W, Numata K, Morimoto M, et al. Role of Sonazoid-enhanced three-dimensional ultrasonography in the evaluation of percutaneous radiofrequency ablation of hepatocellular carcinoma. Eur J Radiol. 2010;75:91–7.
20. Numata K, Fukuda H, Morimoto M, et al. Use of fusion imaging combining contrast-enhanced ultrasonography with a perfubutane-based contrast agent and contrast-enhanced computed tomography for the evaluation of percutaneous radiofrequency ablation of hypervascular hepatocellular carcinoma. Eur J Radiol. 2012;81:2746–53.
21. Kunishi Y, Numata K, Morimoto M, et al. Efcacy of fusion imaging combining sonography and hepatobiliary phase MRI with GdEOB-DTPA to detect small hepatocellular carcinoma. AJR Am J Roentgenol. 2012;198:106–14.
22. Numata K, Fukuda H, Miwa H, et al. Contrast-enhanced ultrasonography fndings using a perfubutane-based contrast agent in patients with early hepatocellular carcinoma. Eur J Radiol. 2014;83:95–102.
23. Numata K, Fukuda H, Nihonmatsu H, et al. Use of vessel patterns on contrast-enhanced ultrasonography using a perfubutane-based contrast agent for the diferential diagnosis of regenerative nodules from early hepatocellular carcinoma or high-grade dysplastic nodules in patients with chronic liver disease. Abdom Imaging. 2015;40:2372–83.
24. Sugimori K, Numata K, Okada M, et al. Central vascular structures as a characteristic fnding of regenerative nodules using hepatobiliary phase gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MRI and arterial dominant phase contrast-enhanced US. J Med Ultrason. 2017;44:89–100.
25. Numata K. Advances in ultrasound systems for hepatic lesions in Japan. J Med Ultrason. 2015;42:297–301.
26. Ishii T, Numata K, Hao Y, et al. Evaluation of hepatocellular carcinoma tumor vascularity using contrast-enhanced ultrasonography as a predictor for local recurrence following radiofrequency ablation. Eur J Radiol. 2017;89:234–41.
27. Hao Y, Numata K, Ishii T, et al. Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma. World J Gastroenterol. 2017;23:3111–21.
28. Minami Y, Kudo M. Imaging modalities for assessment of treatment response to nonsurgical hepatocellular carcinoma therapy: contrast-enhanced US, CT, and MRI. Liver Cancer. 2015;4:106–14.
29. Nakashima Y, Nakashima O, Tanaka M, et al. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. Hepatol Res. 2003;26:142–7.
30. Minami Y, Nishida N, Kudo M. Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI. World J Gastroenterol. 2014;20:4160–6.
31. Nakazawa T, Kokubu S, Shibuya A, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol. 2007;188:480–8.
32. Kudo M, Hatanaka K, Maekawa K. Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid in the management of hepatocellular carcinoma. Oncology. 2010;78:40–5.
33. Shi W, He Y, Ding W, et al. Contrast-enhanced ultrasonography used for post-treatment responses evaluation of radiofrequency ablations for hepatocellular carcinoma: a meta-analysis. Br J Radiol. 2016;89:20150973.
34. Makino Y, Imai Y, Igura T, et al. Feasibility of extracted-overlay fusion imaging for intraoperative treatment evaluation of radiofrequency ablation for hepatocellular carcinoma. Liver Cancer. 2016;5:269–79.
35. Jung EM, Friedrich C, Hofstetter P, et al. Volume navigation with contrast enhanced ultrasound and image fusion for percutaneous interventions: frst results. PLoS One. 2012;7:e33956.
36. Minami T, Minami Y, Chishina H, et al. Combination guidance of contrast-enhanced US and fusion imaging in radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on contrast-enhanced US/Fusion imaging. Oncology. 2014;87:55–62.
37. Min JH, Lim HK, Lim S, et al. Radiofrequency ablation of veryearly-stage hepatocellular carcinoma inconspicuous on fusion imaging with B-mode US: value of fusion imaging with contrastenhanced US. Clin Mol Hepatol. 2014;20:61–70.
38. Seo J, Koizumi N, Funamoto T, et al. Visual servoing for a USguided therapeutic HIFU system by coagulated lesion tracking: a phantom study. Int J Med Robot. 2011;7:237–47.
論文の公開元へ
